沉默调节蛋白4在肝脏疾病发生发展中的作用

谢黎; 张宁萍; 吴健

doi:10.3969/j.issn.1001-5256.2020.02.049

沉默调节蛋白4在肝脏疾病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2020.02.049

1. 复旦大学基础医学院病原生物学系
2. 复旦大学附属中山医院消化科

基金项目:

北京医卫健康公益基金会(YWJKJJHKYJJ-G17014)；国家自然科学基金(81572356,81871997)；科技部重点项目(2016YFE0107400)；

详细信息

中图分类号: R575
计量
- 文章访问数: 867
- HTML全文浏览量: 13
- PDF下载量: 257
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-23
- 出版日期: 2020-02-20

Role of silent information regulator 4 in the development and progression of liver diseases

Department of Medical Microbiology and Parasitology,Fudan University School of Basic Medical Sciences

Research funding:

摘要

摘要:
沉默调节蛋白（SIRT）家族是一类高度保守、依赖烟酰胺腺嘌呤二核苷（NAD+）的去乙酰化酶类,包括7个家族成员（SIRT 1～7）。定位于线粒体的SIRT-4具有去乙酰基酶、ADP-核糖转移酶、依赖NAD+蛋白脂酰胺酶和脱酰酶活性,参与线粒体蛋白翻译后修饰,调节体内多个代谢过程。由于代谢功能障碍与肝脏疾病息息相关,近些年,SIRT-4在肝脏疾病中的作用及调控机制日益受到关注。阐述了SIRT-4在病毒性肝炎、非酒精性脂肪性肝病、肝纤维化以及肝细胞癌等疾病中的作用,为这些肝脏疾病的防治提供新的视角。
- 沉默调节蛋白4 /
- 肝炎,病毒性,人 /
- 非酒精性脂肪性肝病 /
- 肝硬化 /
- 癌,肝细胞
Abstract:
Silent information regulators are a family of highly conserved nicotinamide adenine dinucleotide( NAD+)-dependent deacetylases and has seven members( Sirt1-7). Silent information regulator 4( Sirt4),localized in the mitochondria,possesses the activity of deacetylase,ADP-ribosyltransferase,NAD+-dependent lipoamidase,and deacylase,participates in post-translational modification of mitochondrial proteins,and regulates multiple metabolic processes. Since metabolic dysfunction is closely associated with liver diseases,the role and regulatory mechanism of Sirt4 in liver diseases has attracted more and more attention. This article elaborates on the role of Sirt4 in viral hepatitis,nonalcoholic fatty liver disease,liver fibrosis,and hepatocellular carcinoma,in order to provide new perspectives for the prevention and treatment of these liver diseases.
- sirtuin-4 /
- hepatitis,viral,human /
- non-alcoholic fatty liver disease /
- liver cirrhosis /
- carcinoma,hepatocellular

HTML全文

参考文献(36)

[1] FU M,LIU M,SAUVE AA,et al. Hormonal control of androgen receptor function through SIRT1[J]. Mol Cell Biol,2006,26(21):8122-8135.

[2] NAKAGAWA T,LOMB DJ,HAIGIS MC,et al. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle[J]. Cell,2009,137(3):560-570.

[3] ANDERSON KA,HUYNH FK,FISHER-WELLMAN K,et al.SIRT4 is a lysine deacylase that controls leucine metabolism and insulin secretion[J]. Cell Metab,2017,25(4):838-855.

[4] MIN Z,GAO J,YU Y. The roles of mitochondrial SIRT4 in cellular metabolism[J]. Front Endocrinol(Lausanne),2019,9:783.

[5] HAIGIS MC,MOSTOSLAVSKY R,HAIGIS KM,et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells[J]. Cell,2006,126(5):941-954.

[6] AHUJA N,SCHWER B,CAROBBIO S,et al. Regulation of insulin secretion by SIRT4,a mitochondrial ADP-ribosyltransferase[J]. J Biol Chem,2007,282(46):33583-33592.

[7] DU J,JIANG H,LIN H. Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogues and 32P-NAD[J]. Biochemistry,2009,48(13):2878-2890.

[8] LAURENT G,GERMAN NJ,SAHA AK,et al. SIRT4 controls the balance between lipid synthesis and catabolism by repressing malonyl-Co A decarboxylase[J]. BMC Proc,2012,6(Suppl 3):p30.

[9] FELDMAN JL,BAEZA J,DENU JM. Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins[J]. J Biol Chem,2013,288(43):31350-31356.

[10] VERDIN E,DEQUIEDT F,FISCHLE W,et al. Measurement of mammalian histone deacetylase activity[J]. Methods Enzymol,2004,377:180-196.

[11] PENG C,LU Z,XIE Z,et al. The first identification of lysine malonylation substrates and its regulatory enzyme[J]. Mol Cell Proteomics,2011,10(12):M111. 012658.

[12] MATHIAS RA,GRECO TM,OBERSTEIN A,et al. Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity[J]. Cell,2014,159(7):1615-1625.

[13] DENG JJ,KONG K E,GAO WW,et al. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription[J]. Biochim Biophys Acta Gene Regul Mech,2017,1860(4):491-501.

[14] LUO YX,TANG X,AN XZ,et al. SIRT4 accelerates Ang IIinduced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity[J]. Eur Heart J,2017,38(18):1389-1398.

[15] LANG A,GRETHER-BECK S,SINGH M,et al. MicroRNA-15b regulates mitochondrial ROS production and the senescence-associated secretory phenotype through sirtuin 4/SIRT4[J]. Aging(Albany NY),2016,8(3):484-505.

[16] WU T,LIU YH,FU YC,et al. Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients[J]. Ann Clin Lab Sci,44(4):410-418.

[17] SHETH SG,GORDON FD,CHOPRA S. Nonalcoholic steatohepatitis[J]. Ann Intern Med,1997,126(2):137-145.

[18] GUO L,ZHOU SR,WEI XB,et al. Acetylation of mitochondrial trifunctional proteinα-subunit enhances its stability to promote fatty acid oxidation and is decreased in nonalcoholic fatty liver disease[J]. Mol Cell Biol,2016,36(20):2553-2567.

[19] LAURENT G,de BOER VC,FINLEY LW,et al. SIRT4 represses peroxisome proliferator-activated receptorαactivity to suppress hepatic fat oxidation[J]. Mol Cell Biol,2013,33(22):4552-4561.

[20] LANG A,ANAND R,ALTINOLUK-HAMBCHEN S,et al.SIRT4 interacts with OPA1 and regulates mitochondrial quality control and mitophagy[J]. Aging(Albany NY),2017,9(10):2163-2189.

[21] FARCAS M,GAVREA AA,GULEI D,et al. SIRT1 in the development and treatment of hepatocellular carcinoma[J]. Front Nutr,2019,6:148.

[22] KIM HS,VASSILOPOULOS A,WANG RH,et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity[J]. Cancer Cell,2011,20(4):487-499.

[23] CHEN J,CHAN AW,TO KF,et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling[J]. Hepatology,2013,57(6):2287-2298.

[24] ZHANG R,WANG C,TIAN Y,et al. SIRT5 promotes hepatocellular carcinoma progression by regulating mitochondrial apoptosis[J]. J Cancer,2019,10(16):3871-3882.

[25] WANG JX,YI Y,LI YW,et al. Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection[J]. BMC Cancer,2014,14:297.

[26] HAN LL,JIA L,WU F,et al. Sirtuin6(SIRT6)promotes the EMT of hepatocellular carcinoma by stimulating autophagic degradation of E-cadherin[J]. Mol Cancer Res,2019,17(11):2267-2280.

[27] CHEN X,DING X,WU Q,et al. Monomethyltransferase SET8facilitates hepatocellular carcinoma growth by enhancing aerobic glycolysis[J]. Cell Death Dis,2019,10(4):312.

[28] WANG YS,DU L,LIANG X,et al. Sirtuin 4 depletion promotes hepatocellular carcinoma tumorigenesis through regulating adenosine-monophosphate-activated protein kinase alpha/mammalian target of rapamycin axis in mice[J]. Hepatology,2019,69(4):1614-1631.

[29] YOU M,JOGASURIA A,TAYLOR C,et al. Sirtuin 1 signaling and alcoholic fatty liver disease[J]. Hepatobiliary Surg Nutr,2015,4(2):88-100.

[30] ARTEAGA M,SHANG N,DING X,et al. Inhibition of SIRT2suppresses hepatic fibrosis[J]. Am J Physiol Gastrointest Liver Physiol,2016,310(11):g1155-g1168.

[31] CHENG ST,REN JH,CAI XF,et al. HBx-elevated SIRT2promotes HBV replication and hepatocarcinogenesis[J]. Biochem Biophys Res Commun,2018,496(3):904-910.

[32] KIM JK,NOH JH,JUNG KH,et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b[J]. Hepatology,2013,57(3):1055-1067.

[33] HO L,TITUS AS,BANERJEE KK,et al. SIRT4 regulates ATP homeostasis and mediates a retrograde signaling via AMPK[J]. Aging(Albany NY),2013,5(11):835-849.

[34] SAUNDERS LR,VERDIN E. Sirtuins:Critical regulators at the crossroads between cancer and aging[J]. Oncogene,2007,26(37):5489-5504.

[35] MEI Z,ZHANG X,YI J,et al. Sirtuins in metabolism,DNA repair and cancer[J]. J Exp Clin Cancer Res,2016,35(1):182.

[36] JENNIFER S,LEI L,ANDREW M,et al. Loss of SIRT4 decreases GLT-1-dependent glutamate uptake and increases sensitivity to kainic acid[J]. J Neurochem,2014,131(5):573-581.

施引文献

资源附件(0)

访问统计